Cart
sales@molnova.com
SARS-CoV-2 3CLpro-IN-16
CAS No. 352659-40-6
SARS-CoV-2 3CLpro-IN-16( —— )
Catalog No. M37246 CAS No. 352659-40-6
SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1773 | Get Quote |
|
| 500MG | 3537 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSARS-CoV-2 3CLpro-IN-16
-
NoteResearch use only, not for human use.
-
Brief DescriptionSARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.
-
DescriptionSARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorSARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number352659-40-6
-
Formula Weight294.37
-
Molecular FormulaC17H14N2OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CSCC(=O)N1C=2C=CC=CC2CCC=3C=CC=CC31
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ren P, et al. Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group. J Med Chem. 2023 Aug 18.?
molnova catalog
related products
-
Concizumab
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.
-
DL-Menthol
DL-Menthol has short term toxicity in rats, it plays a role in the induction of surgical anesthesia in fishes, related at least in part to the activation of GABAA receptors.
-
NVP-ACC789
ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
